mProX™ Human AGTR1 Stable Cell Line

Tayler HM, et al. "Altered gene expression within the renin-angiotensin system in normal ageing and ." The journals of gerontology. Series A, Biological sciences and medical sciences, 2023.
In this study, the authors investigated the expression of genes related to the renin-angiotensin system (RAS) in ageing and dementia. They analyzed samples from 48 individuals in the BS0-II group, 44 in the BSIII-IV group, and 85 in the BSV-VI group using qPCR. The expression levels of ACE1, AGTR1, AGTR2, ACE2, LNPEP, and MAS1 were measured using the 2-,àÜ,àÜCq method, and adjusted for reference genes (RPL13 and UBE2D2) and cell-specific calibrator genes (NEUN, GFAP, PECAM). The results showed that ACE1 and AGTR1, markers of classical RAS signalling, were elevated in normal ageing, while AGTR2 gene expression was increased in BSV-VI. On the other hand, markers of protective downstream regulatory RAS signalling (rRAS), including ACE2, MAS1, and LNPEP, were unchanged. In individuals with Alzheimer's disease (AD) and mixed dementia, AGTR1 and AGTR2 gene expression were increased in BSIII-IV and BSV-VI, respectively. MAS1 gene expression was reduced in BSV-VI and negatively correlated with brain amyloid-beta and tau levels. LNPEP gene expression was specifically elevated in vascular dementia. These findings provide new insights into the role of RAS signalling in normal ageing and dementia.
Pubmed: 37813091   DOI: 10.1093/gerona/glad241

Sayed Murad HA, et al. "Molecular docking analysis of AGTR1 antagonists.." Bioinformation, 2023.
Cardiovascular diseases (CVDs) are a major cause of death and morbidity worldwide. The renin-angiotensin system plays a vital role in regulating cardiovascular and renal function. Consequently, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have become the first-line treatments for conditions such as hypertension and heart failure. However, available synthetic medications for treating CVDs have been associated with adverse effects. As a result, this study is investigating the potential of natural compounds to target the type-1 angiotensin II receptor (AGTR1). Using the ZINC database, the researchers screened natural compounds and standard AGTR1 inhibitors against the AGTR1 active site. The results identified five compounds - ZINC85625504, ZINC62001623, ZINC70666587, ZINC06624086, and ZINC95486187 - with similar binding energies to established AGTR1 inhibitors. These compounds were found to interact with critical AGTR1 residues, suggesting their potential as AGTR1 inhibitors. Notably, the hit compounds also exhibited desirable drug-like properties, making them promising candidates for further investigation in managing CVDs.
Pubmed: 37808379   DOI: 10.6026/97320630019284